Background: This study evaluated whether measuring prothrombin time (PT) using particular
reagents of interest predicted apixaban-associated anticoagulant activity in Japanese …

Background Information on apixaban anticoagulant activity is required to prevent major
bleeding or thrombosis during its use. Methods We enrolled 194 patients with nonvalvular …

Our aim is to determine the most appropriate laboratory tests, besides anti-factor Xa (anti-
FXa) chromogenic assays, to estimate the degree of anticoagulation with apixaban and …

Background Depending on the characteristics of patients, the blood concentration of
apixaban can unexpectedly increase, possibly leading to bleeding events. Anti-FXa activity …

Apixaban can significantly prevent stroke events in patients with non-valvular atrial
fibrillation (NVAF), as can be observed from the large, randomized, controlled trial …

In some clinical situations, measurements of anticoagulant effect of apixaban may be
needed. We investigated the inter-and intra-individual apixaban variability in patients with …

There are clinical situations where information about the anticoagulant effects of Apixaban
could be useful. Specialised methods for measuring Apixaban concentrations are not …

Abstract Introduction The direct factor-Xa inhibitor apixaban is approved eg for the
prevention of stroke in patients with atrial fibrillation (AF). Although routine monitoring of …

Abstract Background/Objectives Despite lower major bleeding rates associated with direct
oral anticoagulants (DOACs) as compared to conventional warfarin therapy, bleeding rates …

Aims Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial
recanalization, attributable to endogenous fibrinolysis, which strongly relates to improved …